Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

Donna M Graham1, Vicky M Coyle1, Richard D Kennedy1

  • 1Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE N. Ireland UK.

Current Colorectal Cancer Reports
|June 25, 2016
PubMed

Insights

Colorectal cancer (CRC) subtypes are driven by molecular changes. Advances in genomic testing and immunotherapy offer new targeted treatment strategies for CRC patients.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) development involves key molecular pathways and genetic mutations.
  • Clinicopathological features of CRC subgroups are linked to specific molecular alterations.
  • Current therapeutic strategies targeting CRC molecular aberrations are limited.

Approach:

  • This review details current biomarkers for molecular stratification and treatment allocation in CRC.
  • It covers open and planned precision medicine trials for colorectal cancer.
  • Advances in understanding CRC biology, therapeutic strategies, and technology are outlined.

Key Points:

  • Broader genomic testing and collaborative research are becoming standard in CRC management.
  • Wider mutational spectrum testing is now routine before administering targeted therapies.
  • Immunotherapy shows promise for treating colorectal cancer patients.

Conclusions:

  • Improved understanding of CRC biology drives advancements in precision medicine.
  • Targeted therapies and immunotherapy represent evolving treatment strategies for CRC.
  • Ongoing research and clinical trials are crucial for developing innovative CRC treatments.
Keywords:
BRAFBiomarker stratificationColorectal cancerEGFRHER2Microsatellite instabilityMolecular subtypesPathwaysPersonalized medicine trialsRASTargeted therapyc-MET

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.4K